RENOVORX, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
RENOVORX, INC. (RNXT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.98 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.02, a 7.27% decline year-over-year.
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.10, a 8.33% decline year-over-year.
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.20, a 64.71% decline year-over-year.
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.40, a 7.26% increase year-over-year.
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.02, a 12.82% decline from fiscal 2024.
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.17, a 56.18% decline from fiscal 2023.
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.67, a 10.33% increase from fiscal 2022.
- RENOVORX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.42, a 53.73% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.98 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $1.02 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $1.02 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $0.99 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.86 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $1.10 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $1.17 10-K · filed 2025-04-01 | |||
| 2024-09-30 | $1.18 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $1.18 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $1.20 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $2.67 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $3.10 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $3.12 10-Q · filed 2023-08-16 | |||
| 2023-03-31 | $3.40 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $2.42 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $2.65 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $3.17 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $3.17 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $5.23 10-K · filed 2022-03-30 | |||
| 2021-09-30 | $4.94 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |